
Niche is involved in EU regulatory strategy and clinical implementation, including:
"During my 5 years with Surface Logix Inc., a 25-person US biotech company, we have relied on Niche Science & Technology Ltd. for regulatory, clinical ops and medical writing functions."




Niche began discussing Surface Logix’s clinical ambitions in 2001 as its first asset entered clinical development. Niche was invited to guide the small US biotech team on regulatory strategy and clinical implementation in the EU. Niche began to provide support for the development of all regulatory documentation. The Niche team’s expertise in the preparation of IMPDs, IBs, protocols and assembling and filing of clinical trial applications meant that it quickly and efficiently developed the necessary regulatory submission documentation. In a crucial 24-month period the partnership between the Niche and Surface Logix teams saw delivery of a series of clinical projects for three assets in rapid succession. As the clinical requirements increased, the Surface Logix team relied on Niche to provide a more executive function as part of their role as Legal Representative in addition to providing on the ground project management and monitoring for four clinical trials, for a range of indications. Niche became a crucial component in the clinical trial team.
Niche supported ReCode Therapeutics in launching their first UK patient study, delivering end-to-end clinical and.
read moreChosen as FDL's UK regulatory and clinical operations partner, Niche managed three Phase 1a/b cystic fibrosis studies.
read moreEmbedded in HMR's early-phase work since 2005, Niche has supported their specialist Phase I and II trials with.
read moreBrought in from the very first CTA submission, Niche grew into Pulmocide's fully embedded clinical and regulatory.
read moreNiche functioned as RespiVert's extended clinical and writing team across multiple early-phase respiratory programmes,.
read moreGet our latest news and publications
Sign up to our news letter